Advances in Prognostic and Predictive Biomarkers of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 21548
Special Issue Editor
Special Issue Information
Dear Colleagues,
With the progress of next-generation sequencing (NGS), companion diagnostics (CDx) including driver mutations such as EGFR, ALK, ROS1, BRAF, MET and RET have become widespread. In addition, the PD-L1 IHC test has been added to CDx as a biomarker for immune-checkpoint inhibitors (ICIs). Moreover, biomarker tests for solid tumors include NTRK, microsatellite instability (MSI), and tumor mutation burden (TMB).
In this Special Issue we will discuss the current status and future developments of these biomarkers and CDx. Then, we will clarify the problems of CDx and aim to promote the development of new inspections.
Dr. Tatsuya Nagano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EGFR
- ALK
- ROS1
- BRAF
- MET
- RET
- PD-L1
- companion diagnosis